Annual International Lung Cancer Congress

First-Line TKI Treatment Use in ROS1, BRAF Alterations in Lung Cancer More Controversial

July 29, 2018

According to Tony S. Mok, MD, first-line treatment with tyrosine kinase inhibitors for patients with non–small cell lung cancers harboring uncommon driver mutations can be controversial. Instead, there is more evidence supporting the use of TKIs in the second-line for mutations such as ROS1 and BRAF, he explained during a presentation at the 19th Annual International Lung Cancer Congress.

More Umbrella Trials Needed to Advance Precision Medicine in Lung Cancer, Expert Suggests

July 29, 2018

Further advancements in precision medicine for patients with non–small cell lung cancer necessitate the use of more umbrella trials to evaluate therapies based on molecular aberrations versus tumor types, Vassiliki A. Papadimitrakopoulou, MD, suggested during a presentation at the 19th Annual International Lung Cancer Congress.

Mitsudomi Explains the Best Sequencing Strategies for EGFR+ NSCLC

July 29, 2018

In a presentation at the 19th Annual International Lung Cancer Congress, Tetsuya Mitsudomi, MD, PhD, provided sequencing options to utilize the many available regimens for the best potential survival outcomes for patients with EGFR-mutant non–small cell lung cancer.

Bridging the Gap Between Disparities in Lung Cancer

July 28, 2018

Laurence J. Heifetz, MD, FACP, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses a novel approach to managing disparities in lung cancer care.

Locally Advanced NSCLC Paradigm Benefits From Checkpoint Inhibitors

July 28, 2018

The use of checkpoint inhibition in patients with locally advanced non–small cell lung cancer in combination with chemoradiation, and specifically durvalumab from the PACIFIC trial, has shown the first significant survival benefits in almost 25 years, according to Corey J. Langer, MD.

Immunotherapy Combinations Challenge Standards of Care in NSCLC

July 28, 2018

Combinations with immunotherapy agents have surged ahead with new regimens showing great potential for the treatment of patients with lung cancer, Corey Langer, MD, said during a presentation at the 19th Annual International Lung Cancer Congress (ILCC). Knowledge about a growing number of biomarkers are helping to guide treatment decisions with these combination options, he said, but the one standard of care has not yet been determined.

Integrating Molecular Pathology Into NSCLC Treatment Selection

July 28, 2018

Ignacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer.

Bunn Reviews Neoadjuvant/Adjuvant Approaches for Patients With Lung Cancer

July 27, 2018

In an interview with Targeted Oncology at the 19thAnnual International Lung Cancer Congress, Bunn, professor in the Division of Medical Oncology at the University of Colorado Cancer Center, discussed the potential approaches with neoadjuvant or adjuvant therapies for curing patients with lung cancer. He also shares his own opinions on which approaches might be best.

Molecular Profiling to Inform Treatment Decisions for Patients With NSCLC

July 27, 2018

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non-small cell lung cancer.

Shepherd Says Translational Research in EGFR+ Lung Cancer Thanks to Molecular Pathology

July 27, 2018

In a keynote address by Frances A. Shepherd, MD, FRCPC, OOnt, OC, during the 19th Annual International Lung Cancer Congress, Shepherd expressed that EGFR-mutant non–small cell lung cancer (NSCLC) is a model for how far the field of lung cancer has progressed in the past decade, thanks in large part to molecular pathologists.